Business · 07/08/1998Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Mirapex Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for a patent extension application for Mirapex, a human drug product, as required by law, following a submission to the US Department of Commerce's Commissioner of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →